Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
Completed
Furiex Pharmaceuticals, Inc
Phase 2
2010-04-28
The purpose of this study is to determine the efficacy, safety, and tolerability of different
doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with
irritable bowel syndrome with diarrhea (IBS-d).
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Completed
Furiex Pharmaceuticals, Inc
Phase 3
2012-05-29
The purpose of this study is to determine the efficacy, safety, and tolerability of different
doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants
with diarrhea-predominant irritable bowel syndrome.
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Completed
Furiex Pharmaceuticals, Inc
Phase 3
2012-05-29
The purpose of this study is to determine the efficacy, safety, and tolerability of different
doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants
with diarrhea-predominant irritable bowel syndrome.
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
Completed
Allergan
Phase 4
2016-10-25
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a
day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with
Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to
provide control of their IBS-D symptoms.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
